---
title: "Safety and Efficacy of SGLT2 Inhibitors in Patients With Cancer and Diabetes"
id: "journal-of-the-american-heart-association-11-safety-and-efficacy-of-sodium-glucose-cotransporter-2-inhibitors-in-patients-with-cancer-and-diabetes"
canonical_url: "https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-11-safety-and-efficacy-of-sodium-glucose-cotransporter-2-inhibitors-in-patients-with-cancer-and-diabetes"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "Journal of the American Heart Association"
source_url: "https://www.ahajournals.org/doi/abs/10.1161/JAHA.125.042404?ai=sg&mi=3&af=R"
published_at: "2026-03-10T10:41:02.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Safety and Efficacy of SGLT2 Inhibitors in Patients With Cancer and Diabetes
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-11-safety-and-efficacy-of-sodium-glucose-cotransporter-2-inhibitors-in-patients-with-cancer-and-diabetes
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** Journal of the American Heart Association
- **Source URL:** [Original Journal Publication](https://www.ahajournals.org/doi/abs/10.1161/JAHA.125.042404?ai=sg&mi=3&af=R)
- **Published At:** 2026-03-10T10:41:02.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
Journal of the American Heart Association, Volume 15, Issue 6 , March 17, 2026. BackgroundDiabetes and cancer exhibit a high likelihood of co‐occurrence. Diabetes serves as a risk factor for various forms of cancer and is associated with a poorer prognosis. SGLT2 (sodium‐glucose cotransporter 2) inhibitors (SGLT2i) are effective antidiabetic therapies associated with reduced all‐cause mortality in the general population; however, data among the population with cancer are scarce. We aimed to assess the safety and efficacy of SGLT2i therapy among patients with diabetes and cancer.MethodsA large retrospective, single‐center study including 849 patients diagnosed with diabetes and active cancer. Patients were divided into 2 groups: 169 patients treated with SGLT2i before cancer diagnosis and 680 patients SGLT2i naive. The primary end point was all‐cause mortality. The secondary end point was the composite of cardiovascular outcomes, including heart failure, acute coronary syndrome, and arrhythmias.ResultsAfter a median follow‐up of 48 months (interquartile range, 27–72), all‐cause mortality was significantly lower in the SGLT2i group (67% versus 53%,P=0.001).
## Clinical Analysis & Structured Key Points
Synchronous diabetes and malignancy: study design and population - This report describes a retrospective, single-center analysis enrolling 849 adults with diabetes and active cancer. The cohort was split into two groups: 169 individuals who received a sodium glucose cotransporter-2 inhibitor (SGLT2i) before cancer diagnosis, and 680 individuals who were naïve to SGLT2i therapy. Context and primary objectives - The investigation aimed to characterize safety and efficacy of SGLT2 inhibitors in the specific intersection of diabetes and cancer, acknowledging prior data show mortality benefits in the general diabetic population but limited cancer-specific evidence. Intervention exposure and comparator - Exposure: prior receipt of an SGLT2 inhibitor before cancer diagnosis. - Comparator: no prior SGLT2i exposure during the cancer-diabetes co-morbidity course. Follow-up and outcomes assessed - Median follow-up duration was 48 months (interquartile range 27–72 months). - The primary endpoint was all-cause mortality. - A secondary composite cardiovascular endpoint encompassed heart failure, acute coronary syndrome, and arrhythmias. Key findings on mortality and cardiovascular events - All-cause mortality favored the SGLT2i-treated group, with 67% mortality in the exposed cohort versus 53% in the unexposed cohort (P=0.001). - Multivariable Cox modeling identified SGLT2i exposure as an independent predictor of reduced all-cause mortality (hazard ratio 0.676; 95% CI 0.532–0.860; P=0.001). - Cardiovascular outcomes appeared more frequent in the SGLT2i group (28% vs 16%; P=0.001), driven largely by higher heart failure events (14% vs 7%; P=0.008). - After propensity score matching, SGLT2i remained associated with reduced mortality (P=0.016), but there were no statistically significant differences in the composite cardiovascular outcome (P=0.067). Limitations and certainty - The analysis is retrospective and single-center, which may limit generalizability and introduce residual confounding. - Despite adjustment and matching, causal inference remains constrained without randomized data. - The authors explicitly call for randomized clinical trials to confirm findings and to elucidate potential mechanisms.
## Related Clinical Research

- [Semaglutide and Primary Prevention of MACCE in Obese Adults with T2DM and Rheumatoid Arthritis](https://medichelpline.com/clinical-feed/pubmed-42334436.md) (DOI: 10.1093/ehjcvp/pvag044)
- [Intensive blood pressure control linked to 15% lower 7-year dementia risk](https://medichelpline.com/clinical-feed/medical-news-today-0-intensive-blood-pressure-control-cuts-7-year-dementia-risk-by-15-study-finds.md)
- [My Health is Our Health: AHA and Ascension Seton launch Austin campaign on pregnancy and heart hea](https://medichelpline.com/clinical-feed/aha-news-0-american-heart-association-and-ascension-seton-launch-initiative-to-help-austin.md)
- [Field-of-view confounding in self-supervised cardiac imaging alters genetic discovery](https://medichelpline.com/clinical-feed/medrxiv-9-field-of-view-confounding-shapes-genetic-discovery-from-self-supervised-cardiac.md)
- [Sex and NOS inhibition shape distinct cardiac responses to cardiometabolic stress in older mice](https://medichelpline.com/clinical-feed/biorxiv-6-nitric-oxide-synthase-inhibition-and-biological-sex-define-different-cardiac.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.